Disc Degenerative DiseasePhase 2/3NCT07187362
Comparison of Posterior Cellular Bonegraft Options for Single Level Lumbar Spinal Fusion
A Phase 2/3 study testing Use iliac bone graft, use bone morphogenetic protein and use bone derived allograft MSCs in people with Disc Degenerative Disease and Spine Fusion for Degenerative Spine Disease, run by Midwest Spine & Brain Institute.
Trial summary
This study involves the assessment of alternatives to iliac bone graft during spinal fusion surgery. Four types of bone graft alternatives are being compared to iliac bone graft during the posterior portion of an anterior/posterior one-level lumbar spinal fusion. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Disc Degenerative Disease, Spine Fusion for Degenerative Spine Disease
- What is being tested?
- Use iliac bone graft, use bone morphogenetic protein and use bone derived allograft MSCs
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 119 participants
- Where
- No sites listed yet
- Study dates
- 13 Oct 2015to 31 Jan 2020
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Inclusion Criteria: Single level lumbar degenerative disc disease -
Exclusion Criteria: Degenerative spondylolisthesis >grade 1, lytic spondyolisthesis, infection, stenosis requiring laminectomy, cancer, scoliosis, pregnancy
-
About this study
Official title: Comparison of Posterior Cellular Bonegraft Options for Single Level Lumbar Spinal Fusion: A Randomized Trial
This study involves the assessment of alternatives to iliac bone graft during spinal fusion surgery. Four types of bone graft alternatives are being compared to iliac bone graft during the posterior portion of an anterior/posterior one-level lumbar spinal fusion. If you choose to participate in this study, you will be randomized (like a flip of a coin) to receive either your own iliac bone graft, bone morphogenetic protein (BMP, made from proteins found in the human body that stimulate bone growth), or one of the following stem-cell based bone graft alternatives for the posterior portion of your fusion surgery:
- Orthofix Trinity-made from donor bone and bone marrow stem cells
- Allosource Allostem-made from donor bone and fat stem cells
- Nutech Nucel-made from donor bone and placenta (after birth) stem cells
Read more
Each bone graft alternatives has been approved by the United States Food and Drug Administration (FDA) and is commercially available with the exception that BMP application is considered "off-label". That is, BMP it is not approved for this indication, it is currently indicated for anterior fusion. The volume of bone graft that you will receive is the same for each graph type (approximately 5cc). Approximately 150 patients from the Midwest Spine and Brain Institute are expected to be enrolled in this study. If you choose to take part, your participation will last about 2+ year.
At approximately 9 - 15 months after your surgery, you will be asked to return to the Midwest Spine and Brain Institute to undergo a limited CT scan of the fusion level to determine how you are healing. Your pain level and functional ability will also be evaluated at this visit.
Read the detailed description
Consecutive patients who are surgical candidates for a one-level anterior/posterior lumbar fusion are eligible for inclusion into the study. Inclusion criteria included:
- 18 to 65 years of age.
- Primary degenerative disc disease of one level with or without prior decompression.
- None or up to moderate stenosis that could be treated with a laminotomy
- degenerative spondylolisthesis grade 2 or less.
Exclusion criteria:
- More than single level symptomatic degenerative disc disease.
- Advanced stenosis that needed extensive laminectomy for adequate decompression.
- Lytic spondylolisthesis.
The study proposal underwent IRB review (HealthEast IRB #1510002). All the participants provided written informed consent. After completing IRB approved consent, patients were randomized, by computer generated program, to 5cc IBG or one of 5 other types of PSF osteoinductive bone graft alternatives: bone morphogenic protein (BMP, small Infuse, Medtronic, Memphis, TN), autologous concentrated bone marrow aspirate (BMA) from the iliac crest (combined with 5cc Allo chips), allograft bone marrow derived stem cells (cAlloBone, 5.3cc Trinity Elite, Orthofix, Lewisville, TX), fat derived allograft stem cells (Allostem, AlloSource, Centennial, CO) combined with 5cc morcelized cancellous allograft (cAlloFat), or placental derived allograft stem cells (NuCel, Nutech, Birmingham, Alabama) combined with 5cc morcelized cancellous allograft (cAlloAm). A historical control group of 5cc cancellous freeze-dried allograft (Allo) was used as an inert "negative" control group. There are 27 patients in each group. All anterior fusions used BMP (small Infuse). The decortication technique of the posterior fusion is identical for all patients. All patients have identical fixation instrumentation implanted (anterior lumbar plate and posterior facet screws). Posterior fusions were instrumented to eliminate posterior micromotion and subsequent pseudarthrosis as a confounding variable. All the fusion procedures were performed by the lead author to ensure a uniform surgical technique across all bone graft type groups. Therefore, the surgical technique is as uniform as practically possible to minimize confounding variables related to the surgery with the only variable being the various posterior fusion bone graft materials. Patients are blinded to the posterior type of bone graft. The volume of bone graft is the same for each type, approximately 5cc.
Postoperatively, all patients are followed for a minimum of 2 years. During this time radiographs and lumbar Thin-cut CT scans of the fused level are obtained at approximately one year postoperatively to assess fusion success of both anterior and posterior spinal columns. Specifically for the posterior fusion, if only a unilateral fusion was identified, the fusion was tallied as half fused. The limited (to the levels fused) CT scan had 2.88 mSv radiation exposure, or similar to one year's worth of background radiation. Radiographs at >2 years are reviewed for progressive loss of adjacent segment disc height for assessment of adjacent level degeneration. Secondary endpoints of clinical outcomes are assessed pre- and postoperatively with multiple outcome instruments: visual analog scales (VAS, 0 to 10 scale with greater value is worse pain) for back and leg pain; pain drawing; Oswestry disability index (ODI, 0 to 100 scale with greater value is worse disability); pain medication usage (non-opioid and opioids); and patient self-assessment of procedure success over a minimum 2-year follow-up period. Outcome results are entered by office personnel (blinded to the type of bone graft) into computer spreadsheets, with the treating surgeon blinded to these results. The historical control group consisted of retrospective cohort of consecutive patients which fit the inclusion/exclusion criteria and had their PSF with freeze-dried allograft morcelized bone. Additional surgeries were tracked for all groups, including pseudarthrosis repair, adjacent level decompression, adjacent-level fusion extension, spinal cord stimulator implantation, and posterior instrumentation removal.
- Being tested
- Use iliac bone graft, use bone morphogenetic protein, use bone derived allograft MSCs, Use adipose tissue derived MSCs, Use amnion/placental derived MSCs
- Keywords
- surgery, allograft bone
- Medical subject headings
- Intervertebral Disc Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Use iliac bone graftBiological
use bone morphogenetic proteinBiological
use bone derived allograft MSCsBiological
Use adipose tissue derived MSCsBiological
Use amnion/placental derived MSCsBiological
| Study group | Role | What they receive |
|---|---|---|
| iliac bone graft | Active comparator | old standard of care Receives: Biological: Use iliac bone graft |
| Bone morphogenetic protein | Experimental | Known osteoinductive bone graph Receives: Biological: use bone morphogenetic protein |
| MSCs from bone allograft | Experimental | extracted MSCs from human cadeveric bone Receives: Biological: use bone derived allograft MSCs |
| MSCs from amnion/placental tissue | Experimental | MSCs derived from human afterbirth tissue Receives: Biological: Use amnion/placental derived MSCs |
| MSCs from human adipose tissue | Experimental | MSCs derived from human fat Receives: Biological: Use adipose tissue derived MSCs |
What is being measured
The primary outcome is the main question the study is designed to answer.
Solid spinal fusion
Assessed by thin cut CT scan
Measured: 1 year
Secondary outcomes (1)
Pain and disability
Self-assessment questionnaire
Measured: 1, 2 and 2+ years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2025
- Study start13 Oct 2015
- Primary completion2 Aug 2019
- Study completion31 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Disc Degenerative DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized, prospective
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 119 participants (actual)
Sponsor and investigators
- Lead sponsor
- Midwest Spine & Brain Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Glenn Buttermann, MS, MD, Midwest Spine & Brain Institute
- Investigators
- Glenn R BUTTERMANN, Principal investigator, Midwest Spine & Brain Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07187362
- Sponsor's protocol ID
- HE 15 10 002
- Status last verified
- Oct 2025
- First submitted
- 18 Sep 2025
- Last updated
- 8 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Trial start date began prior to 2017
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Posterior Cellular Bonegraft Options for Single Level Lumbar Spinal Fusion: A Randomized Trial
- ClinicalTrials.gov ID
- NCT07187362
- Acronym / sponsor ID
- HE 15 10 002
- Keywords
- surgery, allograft bone
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 119 participants (actual)
- Lead sponsor
- Midwest Spine & Brain InstituteUniversity, hospital or other
- Study start
- 13 Oct 2015 (actual)
- Primary completion
- 2 Aug 2019 (actual)
- Study completion
- 31 Jan 2020 (actual)
- First posted
- 23 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study involves the assessment of alternatives to iliac bone graft during spinal fusion surgery. Four types of bone graft alternatives are being compared to iliac bone graft during the posterior portion of an anterior/posterior one-level lumbar spinal fusion. If you choose to participate in this study, you will be randomized (like a flip of a coin) to receive either your own iliac bone graft, bone morphogenetic protein (BMP, made from proteins found in the human body that stimulate bone growth), or one of the following stem-cell based bone graft alternatives for the posterior portion of your fusion surgery:
- Orthofix Trinity-made from donor bone and bone marrow stem cells
- Allosource Allostem-made from donor bone and fat stem cells
- Nutech Nucel-made from donor bone and placenta (after birth) stem cells
Each bone graft alternatives has been approved by the United States Food and Drug Administration (FDA) and is commercially available with the exception that BMP application is considered "off-label". That is, BMP it is not approved for this indication, it is currently indicated for anterior fusion. The volume of bone graft that you will receive is the same for each graph type (approximately 5cc). Approximately 150 patients from the Midwest Spine and Brain Institute are expected to be enrolled in this study. If you choose to take part, your participation will last about 2+ year.
At approximately 9 - 15 months after your surgery, you will be asked to return to the Midwest Spine and Brain Institute to undergo a limited CT scan of the fusion level to determine how you are healing. Your pain level and functional ability will also be evaluated at this visit.
Detailed description
Consecutive patients who are surgical candidates for a one-level anterior/posterior lumbar fusion are eligible for inclusion into the study. Inclusion criteria included:
- 18 to 65 years of age.
- Primary degenerative disc disease of one level with or without prior decompression.
- None or up to moderate stenosis that could be treated with a laminotomy
- degenerative spondylolisthesis grade 2 or less.
Exclusion criteria:
- More than single level symptomatic degenerative disc disease.
- Advanced stenosis that needed extensive laminectomy for adequate decompression.
- Lytic spondylolisthesis.
The study proposal underwent IRB review (HealthEast IRB #1510002). All the participants provided written informed consent. After completing IRB approved consent, patients were randomized, by computer generated program, to 5cc IBG or one of 5 other types of PSF osteoinductive bone graft alternatives: bone morphogenic protein (BMP, small Infuse, Medtronic, Memphis, TN), autologous concentrated bone marrow aspirate (BMA) from the iliac crest (combined with 5cc Allo chips), allograft bone marrow derived stem cells (cAlloBone, 5.3cc Trinity Elite, Orthofix, Lewisville, TX), fat derived allograft stem cells (Allostem, AlloSource, Centennial, CO) combined with 5cc morcelized cancellous allograft (cAlloFat), or placental derived allograft stem cells (NuCel, Nutech, Birmingham, Alabama) combined with 5cc morcelized cancellous allograft (cAlloAm). A historical control group of 5cc cancellous freeze-dried allograft (Allo) was used as an inert "negative" control group. There are 27 patients in each group. All anterior fusions used BMP (small Infuse). The decortication technique of the posterior fusion is identical for all patients. All patients have identical fixation instrumentation implanted (anterior lumbar plate and posterior facet screws). Posterior fusions were instrumented to eliminate posterior micromotion and subsequent pseudarthrosis as a confounding variable. All the fusion procedures were performed by the lead author to ensure a uniform surgical technique across all bone graft type groups. Therefore, the surgical technique is as uniform as practically possible to minimize confounding variables related to the surgery with the only variable being the various posterior fusion bone graft materials. Patients are blinded to the posterior type of bone graft. The volume of bone graft is the same for each type, approximately 5cc.
Postoperatively, all patients are followed for a minimum of 2 years. During this time radiographs and lumbar Thin-cut CT scans of the fused level are obtained at approximately one year postoperatively to assess fusion success of both anterior and posterior spinal columns. Specifically for the posterior fusion, if only a unilateral fusion was identified, the fusion was tallied as half fused. The limited (to the levels fused) CT scan had 2.88 mSv radiation exposure, or similar to one year's worth of background radiation. Radiographs at >2 years are reviewed for progressive loss of adjacent segment disc height for assessment of adjacent level degeneration. Secondary endpoints of clinical outcomes are assessed pre- and postoperatively with multiple outcome instruments: visual analog scales (VAS, 0 to 10 scale with greater value is worse pain) for back and leg pain; pain drawing; Oswestry disability index (ODI, 0 to 100 scale with greater value is worse disability); pain medication usage (non-opioid and opioids); and patient self-assessment of procedure success over a minimum 2-year follow-up period. Outcome results are entered by office personnel (blinded to the type of bone graft) into computer spreadsheets, with the treating surgeon blinded to these results. The historical control group consisted of retrospective cohort of consecutive patients which fit the inclusion/exclusion criteria and had their PSF with freeze-dried allograft morcelized bone. Additional surgeries were tracked for all groups, including pseudarthrosis repair, adjacent level decompression, adjacent-level fusion extension, spinal cord stimulator implantation, and posterior instrumentation removal.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 5
- Model description
- randomized, prospective
| Arm | Type | Receives |
|---|---|---|
| iliac bone graft | Active comparator | Biological: Use iliac bone graftold standard of care |
| Bone morphogenetic protein | Experimental | Biological: use bone morphogenetic proteinKnown osteoinductive bone graph |
| MSCs from bone allograft | Experimental | Biological: use bone derived allograft MSCsextracted MSCs from human cadeveric bone |
| MSCs from amnion/placental tissue | Experimental | Biological: Use amnion/placental derived MSCsMSCs derived from human afterbirth tissue |
| MSCs from human adipose tissue | Experimental | Biological: Use adipose tissue derived MSCsMSCs derived from human fat |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Use iliac bone graft | Biological | iliac bone graft |
| use bone morphogenetic protein | Biological | Bone morphogenetic protein |
| use bone derived allograft MSCs | Biological | MSCs from bone allograft |
| Use adipose tissue derived MSCs | Biological | MSCs from human adipose tissue |
| Use amnion/placental derived MSCs | Biological | MSCs from amnion/placental tissue |
Primary outcome
Solid spinal fusion
Time frame: 1 year
Assessed by thin cut CT scan
1 secondary outcome
Pain and disability
Time frame: 1, 2 and 2+ years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2025.
- Individual participant dataSharing planned: No. Trial start date began prior to 2017
Related trials for Disc Degenerative Disease
Not yet recruiting
CANLINK: Evaluation of the Intralink Intradiscal Device for Low Back Pain Due to Degenerative Disc Disease
Degenerative Disc Disease(DDD)
Active, not recruiting
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
Degenerative Disc Disease, Spine Fusion
Not yet recruitingObservational study
Relationship Between Disability, Flexibility, Back Muscles, and Thoracolumbar Fascia in Patients With Lumbar Disc Degeneration
Intervertebral Disc Degeneration
Active, not recruiting
ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs
Degenerative Disc Disease, Disc Degeneration
Active, not recruiting
The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery
Cervical Degenerative Disc Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Glenn R BUTTERMANN principal investigator
Midwest Spine & Brain Institute
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Use iliac bone graft, use bone morphogenetic protein and use bone derived allograft MSCs in people with Disc Degenerative Disease and Spine Fusion for Degenerative Spine Disease, run by Midwest Spine & Brain Institute.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Solid spinal fusion (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2025.